Four years ago, I started @PopVaxIndia with no real knowledge of biology and <$50k in personal funding, convinced that the combination of generative AI for design & RNA for delivery would unlock a new class of vaccines & therapeutics against diseases resistant to legacy methods.
Today, I’m excited to announce that the clinical batch of PVX-001, our open-source broadly-protective COVID-19 vaccine candidate built on our own RNA platform, has been manufactured at our RNA Foundry in Hyderabad, and it will enter clinical trials in Australia in a few months.
In honour of this milestone, I’m publishing the v/acc manifesto – PopVax's plan to save 1 million lives each year by massively accelerating vaccine development. Read it at the link below:
I sincerely thank @VitalikButerin, the @GatesFoundation, @coeff_giving, and @RenPhilanthropy, the funders who have made all of this possible, as well as the many wonderful people across the world who’ve helped and supported us along the way.
I’m also delighted to welcome @moskov & @CariTuna’s Good Ventures, @viswacolluru, @dhaval_shroff, @AaryamanVir, @therishidesai, Mirsada Vins, and Saurabh Maheshwari into the PopVax family as our first outside equity investors.
It’s time to accelerate vaccine development! We’re developing vaccines against HCV, TB, Strep A, and malaria, which collectively take 2.4 million lives/year, and we plan to take them all into clinical trials by next year. If you’d like to join us, go to popvax.com/jobs.